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A distinctive feature of chronic human immunodeficiency virus type 1 (HIV-1) infection is the presence of multiple
coexisting genetic variants, or subpopulations, that comprise the HIV-1 population detected in the peripheral blood.
Analysis of HIV-1 RNA decay dynamics during the initiation of highly active antiretroviral therapy (HAART) has
been a valuable tool for modeling the life span of infected cells that produce the bulk HIV-1 population. However,
different HIV-1 target cells may have different turnover rates, and it is not clear whether the bulk HIV-1 RNA decay
rate actually represents a composite of the decay rates of viral subpopulations compartmentalized in different
cellular subsets with different life spans. Using heteroduplex tracking assays targeting the highly variable V3 or
V4-V5 regions of the HIV-1 env gene in eight subjects, we found that all detectable coexisting HIV-1 variants in the
peripheral blood generally decayed at similar rates during the initiation of HAART, suggesting that all of the
variants were produced by cells with similar life spans. Furthermore, single genome amplification and coreceptor
phenotyping revealed that in two subjects coexisting HIV-1 variants with distinct CXCR4 or CCR5 coreceptor
phenotypes decayed with similar rates. Also, in nine additional subjects, recombination and a lack of genetic
compartmentalization between X4 and R5 variants were observed, suggesting an overlap in host cell range. Our
results suggest that the HIV-1 env subpopulations detectable in the peripheral blood are produced by cells with
similar life spans and are not genetically isolated within particular cell types.
Infection with human immunodeficiency virus type 1
(HIV-1) is typically established by one or a few variants that
give rise to an initially homogeneous viral population (12, 19,
38, 45). As infection progresses into the chronic phase, se-
quence diversification occurs throughout the viral genome,
most dramatically in the envelope gene (env), as a result of
selection of humoral and cytotoxic T-lymphocyte immune es-
cape mutations (6, 20, 44, 74, 97). Sequence diversity in the env
gene is clustered in variable regions, termed V1 through V5,
that encode surface loops in the Env protein that are important
targets of the host antibody response (20). Diversification of
env results in the presence of multiple, coexisting env variants
in the peripheral blood that continually evolve during the
course of infection (31, 41).
Typically, the HIV-1 population early after infection uses
CCR5 as the coreceptor (R5) (38, 93, 99, 101), and variants
that can use CXCR4 (X4) arise later in the disease course in
approximately one-half of individuals infected with subtype B
virus (10, 42). A major determinant of coreceptor use is found
in the V3 loop, and sequence evolution in this region is often
linked to the virus’s ability to use CXCR4 (17, 36, 54). After
the emergence of X4 virus, env genes encoding both CCR5 and
CXCR4 tropism can coexist for extended periods of time,
maintaining a diverse V3 population (10, 54, 85). Variation in
R5 Env proteins can also influence the ability of a virus to
utilize various levels of CD4 and CCR5 found on different cell
types, such as macrophages and T cells (23, 25, 64, 67, 89, 95).
Distinct biological characteristics encoded by different env
variants, such as coreceptor use, cellular tropism, and sensitiv-
ity to immune pressure, may drive, or result from, HIV-1
compartmentalization. Genetic compartmentalization of HIV-1
variants has been well documented in anatomical compart-
ments, such as the spleen (9, 18, 24), central nervous system (7,
29, 30, 43, 56, 73), and genital tract (13, 39, 60, 65, 70), and in
different cellular compartments, such as monocyte/macro-
phage and CD4 T cells (21, 47). Divergent coreceptor tro-
pism in particular may lead to compartmentalization of virus in
different cellular subsets. For example, both naïve and memory
T lymphocytes express CXCR4 but differentially express CCR5
and have been shown to harbor unequal proportions of
CXCR4- and CCR5-tropic viral variants that are concordant
with their distinct coreceptor expression patterns (3, 91).
While genetic compartmentalization of HIV-1 between an-
atomically or cellularly segregated sequences has been exten-
sively explored, evidence is limited as to the extent to which the
coexisting env subpopulations circulating in the peripheral
blood represent virus emanating from compartmentalized pop-
ulations replicating independently of each other and in differ-
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ent cellular subsets. Although this question is challenging to
address in the context of an infected individual, one approach
stems from the examination of the rate of decay of HIV-1
RNA during the initiation of highly active antiretroviral ther-
apy (HAART). Effective HAART prevents new rounds of
HIV-1 infection, but cells already infected by HIV-1 continue
to produce virus, and therefore the rate of viral RNA decay
during effective HAART reflects the life span of the HIV-1-
producing cells. This strategy was initially used by Ho et al. and
Wei et al. (34, 96) to characterize the turnover rate of HIV-
1-infected cells. These and subsequent studies (4, 49, 62, 63)
suggested that the average life span of infected cells that pro-
duce 99% or more of the bulk HIV-1 population in the pe-
ripheral blood is short, with a half-life of 1 to 2 days, presum-
ably reflecting the life span of activated T cells, whereas cells
producing 1% or less of the population have a half-life mea-
sured in weeks, illustrated by a biphasic decay curve. However,
the bulk HIV-1 RNA decay rate of the first phase may over-
simplify the dynamics of the underlying viral genetic subpopu-
lations because this rate may represent an average without
accounting for possible moderate differences between decay
rates of coexisting variants, as might be the case for variants
infecting cellular subsets in different stages of maturation or
activation (22, 59, 100). Based on this model, two or more
coexisting viral populations with the same rates of decay during
HAART could be presumed to be produced by the same cel-
lular subset or, at minimum, two or more subsets with the same
turnover rate. Conversely, the observation of different rates of
decay would suggest that different cellular subsets are contrib-
uting toward a complex mixture of compartmentalized viral
subpopulations.
In this study we characterized the decay rates of coexisting
HIV-1 env variants in the peripheral blood of eight subjects ini-
tiating HAART. In two of these subjects, who possessed both
CCR5- and CXCR4-tropic Env variants, we analyzed the decay
rates of each phenotypically divergent env subpopulation. Fur-
thermore, in an additional nine subjects, we characterized the
degree of recombination between the R5 and X4 subpopulations
and the degree to which each subpopulation was genetically com-
partmentalized. We found that all detectible HIV-1 env variants
in the peripheral blood, regardless of coreceptor tropism pheno-
type, decayed with similar rates during the initiation of HAART.
In addition, we provide evidence of recombination and a lack of
compartmentalization between coexisting X4 and R5 subpopula-
tions, consistent with the overlap in their target host-cell popula-
tions. Our findings suggest that the detectable HIV-1 env variants
that coexist in the peripheral blood are produced by cells with
similar life spans and, by this measure, are not compartmentalized
in particular cell types.
MATERIALS AND METHODS
Study subjects and sampling. Blood plasma samples used for the variant decay
analysis were obtained from subjects initiating HAART who were recruited
either through a previously described study carried out at the University of
California, San Francisco (subjects 4015, 4021, 4022, 4030, and 5005) (87) or at
the University of North Carolina, Chapel Hill (subjects 101, 106, 108, and 109),
specifically for this study. Sampling of blood plasma was carried out on the day
of treatment initiation and at 1- to 7-day intervals posttreatment initiation; the
median time between samplings for all subjects was 3 days.
Additional blood plasma samples used for the analysis of recombination and
compartmentalization in populations with mixed coreceptor use were excess
tissue obtained from the baseline blood draw of subjects participating in the
virology substudy of a ritonavir efficacy trial described previously (8) (subjects
1314, 1077, and 1551) or from baseline blood draws of subjects entering AIDS
Clinical Trial Group 359 described elsewhere (subjects 432, 135, 139, 411, 413,
and 310) (27). In all cases, written, informed consent was obtained and all
protocols were subject to approval by the Institutional Review Board.
HTA and decay analysis. Viral RNA was extracted from virus particles pel-
leted from 1 ml of blood plasma (25,000  g for 1.5 h) using a QiaAMP Viral
RNA Kit (Qiagen, Chatsworth, CA). Two 5-l aliquots of the 60-l eluate were
amplified in parallel using a OneStep RT-PCR kit (Qiagen, Chatsworth, CA).
The PCR thermocycling procedures, the primers used to amplify the V3 and
V4-V5 regions, and the heteroduplex tracking assays (HTAs) have been previ-
ously described (14, 31, 54). Briefly, PCR products were annealed to a radiola-
beled probe to generate heteroduplexes, which were then separated in a poly-
acrylamide gel. Gel-separated heteroduplexes were visualized by autoradiography
and quantitated on a Storm 840 phosphorimager using the ImageQuant software
(Molecular Dynamics/GE, Pittsburgh, PA). The HTA was modified for this study
by using a biotin-radiolabeled probe to facilitate isolation and sequencing of
HTA bands, as described elsewhere (79). All samples were analyzed in duplicate
to verify sampling reproducibility. Samples and time points that could not be
reproducibly sampled were excluded from the analysis. Viral RNA loads (VLs)
of individual variants were calculated as a product of the total viral RNA load
and the fractional abundance of each variant. Variant half-lives were calculated
using the time points between which VL was declining.
Single genome amplification (SGA). Viral RNA was extracted as described
above. RNA was reverse transcribed using a Superscript III Reverse Transcrip-
tase System (Invitrogen, CA) and oligo(dT). A region of the HIV-1 genome
encompassing env through 3 U3 was amplified using a limiting dilution, semi-
nested PCR according to a method initially described by Simmonds et al. (82)
and Edmonson and Mullins (16) and then modified by Palmer et al. (61) and
Salazar-Gonzalez et al. (76). Primers and thermocycling procedures for ampli-
fication and sequencing were used as previously described in Keele et al. (38) but
modified by replacing the downstream env amplification primer set with a primer
that captures the U3, the sequence of which is 5-AAGCACTCAAGGCAAGC
TTTATTG-3.
Coreceptor tropism analysis. Coreceptor phenotype was predicted based on
V3 sequences of extracted HTA bands and SGA amplicons using a position-
specific scoring matrix (PSSM) generated using a training set of V3 sequences
from envelopes with known coreceptor phenotypes on indicator cells expressing
CD4 and either CXCR4 or CCR5 (36). PSSM was implemented through the web
portal http://ubik.microbiol.washington.edu/computing/pssm/.
Phenotypic analysis was carried out as previously described by Kirchherr et al.
(40) but with modifications. Briefly, a cytomegalovirus (CMV) promoter con-
taining a 3 tag matching the 5 SGA primer binding site was linked to env SGA
amplicons using overlapping PCR. For the CMV-env linking PCR, the 5 primer
sequence is specific for the start of the CMV promoter (5-AGTAATCAATTA
CGGGGTCATTAGTTCAT-3), and the downstream primer (5-TGGGTGGC
TCTGAAAAGAGCCTTTGGGCTGCTGGCTCAGCTCGTCTCATTCTTT
C-3) is specific for a sequence just 3 of the end of env and contains a histone
(H1e) mRNA 3 stem-loop tag (underlined) for increased transcript stability.
CMV-env amplicons were cotransfected with the pNL4-3.Luc.RE plasmid,
obtained from the NIH AIDS Research and Reference Reagent Program (32),
to generate a pseudotyped, single-cycle luciferase reporter virus. The coreceptor
phenotype of pseudotyped virus was assessed on U87.CD4 indicator cell lines,
expressing either CXCR4 or CCR5, obtained from the NIH AIDS Research and
Reference Reagent Program (2).
Compartmentalization and recombination analysis. All sequence alignments
were generated using the program MAFFT (multiple alignment using fast Fou-
rier transform) (37). Maximum-likelihood phylogenies were generated in PhyML
using the HKY85 substitution rate model with the following parameters: use of
four substitution rate categories and estimations of the transition/transversion
rate ratio, proportion of invariant sites, and the gamma distribution parameter
(26). A version of the Slatkin-Maddison (SM) test for gene flow was imple-
mented using HyPhy (69, 83), and measures of KST* were obtained using the
program DnaSP (75). KST* is calculated as described by Hudson, Boos, and
Kaplan (35). Briefly, KST*  1  (KS*/KT), where KS* is the weighted average of
the log of the pairwise differences within each of the two potentially compart-
mentalized subpopulations, and KT is the average number of pairwise differences
between sequences, irrespective of their grouping. For both SM and KST* tests,
comparison of the observed result to the distribution of 1,000 random permu-
tations of the data was used to obtain a P value. Recombination between X4 and
R5 variants was detected in sequence alignments using the bootscan/RECSCAN
analysis implemented in the Recombination Detection Program 3 (50, 78).
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Bootscanning was carried out using a 200-bp window with a 20-bp step, and
trees were constructed using the Jukes-Cantor model with 1,000 bootstrap
replicates.
Nucleotide sequence accession numbers. Sequences determined in this study
have been deposited in the GenBank database under accession numbers
FJ798320 to FJ798580.
RESULTS
Decay rates do not vary between detectable env variants that
coexist in the peripheral blood. We examined the decay rates
of V4-V5 or V3 env variants in chronically infected subjects
initiating HAART to characterize the life span of infected cells
that produce coexisting genetic variants in the peripheral
blood. Blood plasma samples from eight subjects were drawn
every 1 to 7 days after the initiation of therapy, with a median
interval of 3 days, for up to 3 weeks or over a 1- to 2-log10 drop
in total VL. All subjects in this study achieved suppression of
VL to below detectable levels. RNA was extracted from the
plasma samples and then amplified by reverse transcription-
PCR to generate amplicons of the variable regions V4-V5 or
V3, which were then subjected to HTAs to resolve the coex-
FIG. 1. HTA and variant decay analysis of V3 and V4-V5 envelope regions for subjects 106 (A and B) and 108 (C and D). Left panels depict
HTA gel lanes for the first and last time points. Numbered arrows designate reproducible HTA variants. Asterisks indicate single-stranded probe
bands. Right panels are plots of the VLs for individual variants (Var) at each time point sampled. Data points and error bars are the means and
ranges, respectively, for two replicates. In subject 108, a decline in VL was not seen until after the second sampling time point; therefore, the decay
rate was calculated from the second time point in this subject.
TABLE 1. Subject characteristics and virus decay rates
Subject
no.
















101d NAe 2 4.5 201 1.9 2.30 19 1.09 (V4-V5)
106 3 7 4.7 421 2.3 0.90f 5 1.14 (V3)
108 3 5 4.3 158 1.6 0.76 2 1.16 (V4-V5)
109d 2 4 4.9 23 2.1 1.09 11 1.24 (V4-V5)
4015 NA 2 5.1 NA 1.4 2.14 9 1.73
4021 NA 9 5.0 NA 1.0 1.20 2 2.0
4022 NA 4 4.6 NA 1.9 2.09 3 1.58
5005 NA 4 5.3 NA 1.5 2.27 2 1.60
a t1/2, half-life.
b Percent relative abundance of the least abundant variant detected.
c Maximum (Max) difference (n-fold) in the half-life between any two variants.
d Subjects with mixed tropic virus populations.
e NA, data not available.
f Calculated using the first and last time points.
g CD4 count, no. of CD4 T cells/microliter of blood.
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isting sequence variants. The relative abundance of V4-V5 or
V3 variants, potentially comprising as little as 1 to 3% of the
total population, was measured by phosphorimaging analysis
of HTA bands (71, 79). Duplicate reverse transcription-PCRs
were analyzed to ensure sampling reproducibility; the ability to
analyze duplicate samples to validate the quality of sampling is
a key feature of the HTA strategy as the HTA pattern of two
identical, complex populations will appear different if they are
not adequately sampled (33); however, the HTA pattern rep-
resents only variants whose sequence differences cause a shift
in migration rate. While much of the diversity in these highly
variable regions of the genome is captured using this tech-
nique, in this work we are testing the hypothesis that these
HTA variants are markers of potentially compartmentalized
populations.
The decay curves of V4-V5 and V3 HTA variants from two
representative subjects are depicted Fig. 1. The log10 magni-
tude of the VL drop, the half-life (days) of the bulk VL, and
the maximum differences in half-life for the env variants de-
tected in each subject are shown in Table 1. In all but one
subject, virus decay appeared monophasic over the first 1- to
2-log10 decline in VL. In subject 106, the VL decay appeared
more rapid between the first and second time points (days 0
and 1), with an apparent half-life of 0.28 days (based on a
single time point), than the VL decline between the second and
fifth time points, with an apparent half-life of 2.22 days (Fig.
1a). The median half-life of the bulk VL decay rate for these
subjects was 1.7 days. The decay rates of either V3 or V4-V5
variants within each subject did not vary significantly; the me-
dian value for the greatest differences between any two variants
within a subject was 1.6-fold and did not exceed 2-fold within
any subject, likely within the margin of error of this assay. The
minor variation in decay rates of variants did not correlate with
their relative abundance (Table 1). Thus, for variants compris-
ing as little as 2% of the detected population and representing
the first phase of decay, we conclude the following: (i) variants
are not compartmentalized in anatomical locations or cellular
compartments that are differentially targeted by antiviral ac-
tivity; (ii) the life spans of potentially different, virus-producing
cellular subsets do not differ to a significant degree for those
cells producing the major variants of env; and (iii) variants are
not otherwise compartmentalized in a manner that differen-
tially affects their rates of decay.
Decay rates do not differ between X4 and R5 variants in the
first phase of decay. The ability of a virus to use CXCR4
efficiently may allow infection of a different subset of target
cells and hence may result in compartmentalization of X4 and
R5 variants in cell types that differentially express these core-
ceptors, such as memory and naïve T-cell subsets (5). Many X4
variants retain the ability to enter cells using CCR5 (i.e., dual-
tropic) although it is not clear this ability is utilized in vivo (48,
98). Furthermore, naïve and memory T-cell subsets have been
shown to be preferentially infected by CXCR4 or CCR5 vari-
ants, respectively (3, 91).
We identified two subjects from the analysis described above
who had coexisting CXCR4- and CCR5-tropic populations,
which allowed us to determine the relative rates of decay of X4
and R5 variants specifically. Coreceptor usage was assessed by
first using PSSM, followed by phenotypic analysis of the en-
coded Env protein in a pseudotyped virus entry assay, for a
subset of sequences. One subject (109) had a viral population
with both X4 and R5 variants identified by PSSM and con-
firmed in an entry assay. In the other subject (101), distinct V3
variants failed to meet the cutoff value for a CXCR4 tropism
designation by PSSM but exhibited strong CXCR4-tropic ac-
tivity in the entry assay. In both of these subjects, X4 variants
retained some ability to use CCR5.
HTA analysis of the V3 and V4-V5 regions of env of virus
from subject 109 revealed two and four HTA variants, respec-
tively (Fig. 2A and B). Recovery and sequencing of HTA
bands, along with SGA and phylogenetic and phenotypic anal-
ysis of full-length env genes from the first time point, allowed
us to link env sequences and their coreceptor usage phenotypes
FIG. 2. HTA variant decay analysis of V3 and V4-V5 envelope
regions for subjects 109 (A and B) and 101 (C) (V4-V5 only). Left
panels depict HTA gel lanes for the first and last time points. Num-
bered arrows designate reproducible HTA variants. Single and double
asterisks indicate single-stranded and double-stranded probe bands,
respectively. Right panels are plots of the VLs for individual variants
(Var) at each time point sampled. Data points and error bars are the
means and ranges, respectively, for two replicates. Dashed lines indi-
cate V3 and V4-V5 HTA variants linked to X4 usage.
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to the specific V3 and V4-V5 HTA bands for this subject. For
example, X4 and R5 V3 variants formed distinct phylogenetic
lineages that were each represented by one of the two HTA
variants (Fig. 3A), and V4-V5 HTA variants were linked to X4
V3 sequences by the presence of a deletion in each variable
loop (data not shown). The full-length env sequences also
formed distinct phylogenetic lineages according to V3 geno-
type and coreceptor phenotype (Fig. 3B). The decay of X4-
and R5-linked V3 and V4-V5 HTA variants is depicted in
Fig. 2A and B, respectively. The total VL decayed with a
half-life of 2.3 days, and over the course of a 2-log10 drop in
VL, there was no significant difference in the decay rates of
HTA variants relative to each other in subject 109 (Fig. 2A
and B; Table 1).
HTA analysis of virus from subject 101 revealed two variants
in the V4-V5 region that decayed with similar rates (Fig. 2C
and Table 1). However, we were not able to amplify the V3
region from this subject, presumably as a result of subsequently
identified V3 primer binding site mismatches in this viral pop-
ulation. In an alternative approach taken for this subject, SGA
was carried out on each time point in order to assess the
change in the relative proportions of all SGA-amplified env
variants as VL declined. env sequences that exhibited strong
X4 usage in the entry assay clustered together in a phyloge-
netic tree, as did their V3 sequences, indicating linkage to
coreceptor use (Fig. 4). While not meeting the threshold value
for X4 usage according to PSSM, these V3 variants had dis-
tinctly higher PSSM values and were more positively charged
relative to the rest of the population. V4-V5 genotypes were
only weakly linked to tropism (data not shown). Weak X4 entry
activity was detected in some envelopes whose sequences were
intermingled with those of exclusively R5 envelopes (Fig. 4A)
although the biological significance of this low-level X4 activity
is unclear.
The decay rate of the total VL for subject 101 was a half-life
of 2.3 days, and over the course of a 2-log10 drop in VL, there
was no significant difference in the decay rates of V4-V5 HTA
variants relative to each other (Fig. 2C and Table 1). In addi-
tion, we did not detect a significant change in the proportion of
env sequence variants, sampled by SGA, that clustered with
phenotypically identified X4 or R5 variants at the two time
points following initiation of therapy. X4 variants constituted
26% of the amplicons in the first time point and 20% in the
third time point (P  0.7) (Fig. 4A). That we did not detect
differential decay of X4 versus R5 variants in subjects 101 or
109 leads us to conclude that either (i) the bulk of the tropism
variants are not compartmentalized in different cellular sub-
sets, or (ii) while tropism variants may be compartmentalized
in different cellular subsets, these infected cells have similar
life spans when productively infected. Furthermore, any differ-
ential effects that X4 or R5 infection may have on the life span
of the infected cell or any differences in susceptibility of these
tropic variants to antiviral inhibition are not apparent in these
data.
CXCR4- and CCR5-tropic variants exhibit limited genetic
compartmentalization in the peripheral blood. We next exam-
ined the potential genetic compartmentalization of coexisting
R5 and X4 variants using an alternative approach. For this
analysis, we included the entry samples of the two subjects
identified above (101 and 109) and an additional nine subjects,
obtained from studies described in the Materials and Methods
section, with coexisting X4 and R5 subpopulations identified
FIG. 3. Maximum-likelihood phylogenies of the V3 region (A) and full-length env (B) for subject 109. Node labels represent bootstrap values
using 100 replicates. Italicized, bolded tip labels indicate env variants predicted to be X4 by PSSM. Circles indicate an entry assay R5 phenotype;
squares indicate an entry assay X4 phenotype. The V3 tree was rooted at the midpoint. The env tree was rooted using the env sequence of the
molecular clone YU2. V3 HTA variant sequences 1 and 2 correspond to variants in Fig. 2A.
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by PSSM analysis of V3 sequences. Using SGA, which elimi-
nates confounding recombination during PCR, we generated
amplicons containing env, nef, and the U3 region of the viral
genome and carried out PSSM and phenotypic analysis on a
representative subset of env variants from each subject. Phe-
notypic analysis was consistent with the result of the PSSM
analysis for every amplicon tested in all but subject 101, as
described above. CXCR4-tropic variants from all but two sub-
jects in this study (138 and 411) also exhibited CCR5-tropic
activity in the reporter assay but will be referred to as X4
variants. In many subjects, phylogenetic analysis of env se-
quences showed a deep branch point between the R5 se-
quences and a monophyletic group (i.e., a group that has de-
scended from a single ancestral virus) of X4 sequences,
suggesting that the outgrowth of X4 variants derives from a
clonal event. Representative examples of phylogenies of se-
FIG. 4. Maximum-likelihood phylogenies of env (A) and V3 (B) sequences from day 0 (TP1) and day 14 (TP3) for subject 101. Node labels
represent bootstrap values from 100 replicates. Trees were rooted using the molecular clone YU2. Closed circles indicate an entry assay R5
phenotype, squares indicate an entry assay X4 phenotype, and open circles indicate dual-tropic envelopes with weak X4 usage in an entry
assay.
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quences encompassing V1 of env through the 3 U3 from three
subjects are depicted in Fig. 5.
If these X4 and R5 variants exist in distinct compartments
with no migration of viruses between compartments, then the
independent evolution of these virus subpopulations will pro-
duce a number of evolutionary signatures in regions of the
genome outside of V3. We looked for these signatures using
two methods applied to sequences from three regions of the
genome: the V4-V5 region of env, the gp41 region of env, and
the U3 region of the long terminal repeat. First, we used the
SM test (83) to investigate whether independent evolution of
X4 and R5 variants in distinct compartments had produced
similar phylogenetic patterns in all genome regions. Essen-
tially, our use of the SM test examines the expectation that
X4 viruses should form a monophyletic group, regardless of
the genome region used to build the tree, if this group is
compartmentalized. Second, we used a distance-based metric,
KST* (see Materials and Methods) (34, 74, 89), to investigate
whether independent evolution of X4 and R5 variants was
occurring in distinct compartments and producing genetic dif-
ferentiation between the compartments in regions outside of
V3. The KST* statistic is a measure of whether the genetic
distance (number of nucleotide differences) between the X4
and R5 subpopulations is significantly greater than the genetic
distance among viruses within the X4 or R5 subpopulations.
Gene flow between compartments would erode both of these
signatures of independent evolution, and gene flow is expected
to have the strongest impact on genomic regions that are most
distant from V3, due to the increased likelihood of recombi-
nation.
Observed SM and KST values were compared to the distri-
bution of 1,000 random permutations of branches or sequences
to determine the level of significance of separation. Because
X4 and R5 subgroups were essentially defined by their V3
genotypes, which in most subjects were monophyletic groups
with highly similar genotypes, recombination events were in-
ferred when the sequences of the regions analyzed did not
cluster according to their linked V3 genotype, indicated by
migration events in the SM analysis. However, a lack of com-
partmentalization can result in increased sequence homogene-
ity in regions distal to V3, and detection of recombination
between X4 and R5 sequences in these regions is possible only
in cases where there remain strong phylogenetic signals that
result in a well-supported tree.
The analysis revealed statistical support, by both KST and
SM measures, for compartmentalization of two genetic popu-
lations defined by coreceptor use for markers proximal to V3,
such as V4-V5 (Fig. 6). This would be expected as mutations
closer to the population-defining V3 sequence would likely
persist in linkage disequilibrium for a longer period of time
after the outgrowth of the X4 V3 mutations, especially if they
are functionally linked to V3. However, in most subjects, SM
migration events between the R5 and X4 populations were
increased in regions more distal to V3, such as U3 (Fig. 6A),
indicating that these populations were replicating at least part
of the time in a shared cell type, providing the opportunity for
recombination. Representative examples of detected recombi-
nation between X4 and R5 sequences and the predicted loca-
tion of breakpoints, in these cases outside of gp120, are illus-
trated in Fig. 7. This result is consistent with previous
observations of recombination between X4 and R5 viruses
made using different methods (51, 77, 92). We also observed
FIG. 5. Maximum-likelihood phylogenies of sequences encompassing env (starting at V1), nef, and U3 from three representative subjects (1551,
135, and 413) with distinct X4/dual and R5 populations. Node labels represent bootstrap values from 100 replicates. Italicized, bolded tip labels
indicate env variants predicted to be X4 by PSSM and confirmed in an entry assay.
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decreasing values of genetic differentiation between X4 and R5
groups, as measured by KST, for regions farther from V3 (Fig.
6b). However, in several subjects (135, 411, 432, and 1314) a
compartmentalization signal in the U3 region remained statis-
tically significant, if decreased, by both measures (Fig. 6, bot-
tom panels). Taken together, these results show that while X4
and R5 env variants are genetically distinct, in many of our
subjects there is little evidence of genetic compartmentaliza-
tion between X4 and R5 variants in regions outside of env, such
as in the U3.
DISCUSSION
There are several reasons to hypothesize that variants that
appear in the blood are potentially compartmentalized. Pre-
vious studies have demonstrated compartmentalization of
HIV-1 variants between different anatomical compartments,
such as the central nervous system, genital tract, and differ-
ent lymphoid tissues (13, 15, 24, 28, 39, 43, 70, 73, 77, 81,
90), as well as tissue microenvironments (24). The gut-as-
sociated lymphoid tissue, in particular, represents a major
source of active replication of potentially compartmental-
ized CCR5-tropic virus populations (1, 68, 90, 94). It is
possible that virus spatially compartmentalized in these an-
atomical sites may be represented as distinct variants in the
peripheral blood. Because the initiation of HAART
abruptly blocks new rounds of HIV-1 infection, presumably
without impacting viral RNA production from cells already
infected, different decay rates of compartmentalized vari-
ants following suppression of viral replication should reflect
different life spans of the cells from which they are emerg-
ing. Viral populations compartmentalized in either cell
types or tissues that experience differential drug exposure
may also decay at different rates if viral replication contin-
ues at some level in the presence of a suboptimal drug
concentration. However, our observation that all detectable
HIV-1 genetic variants declined at comparable rates sug-
gests that the vast majority of the coexisting HIV-1 sub-
populations in the peripheral blood are not compartmental-
ized either in cell types with different life spans or in cells or
tissues with various degrees of antiretroviral drug bioavail-
ability.
Our use of the HTA allowed for relatively sensitive detec-
tion of variants potentially comprising as little as 1 to 3% of the
population (33, 79). However, one important limitation of this
study is the sensitivity for detection of minority viral popula-
tions below this 1% threshold, which may be produced by cells
with different life spans. Such viral populations almost cer-
tainly exist, based on the biphasic decay kinetics of the bulk
HIV-1 RNA load during HAART (4, 49, 62). It has been
hypothesized that the second phase of decay of the bulk HIV-1
RNA load represents virus produced by cells with a longer life
span, presumably cells of the monocyte lineage. Compartmen-
talization of viral DNA populations between CD4 T cells and
monocytes has been reported (21, 47, 102), and assuming that
monocytes have longer half-lives relative to activated CD4 T
cells, variants compartmentalized in these different cell types
would be expected to exhibit different rates of decay during
HAART (11, 34, 62, 96). However, the proportion of variants
compartmentalized in productively infected monocytes may be
FIG. 6. Analysis of compartmentalization of four genomic regions between X4 and R5 variants. (A) SM test for branch migration events
between X4 and R5 sequences (top) and corresponding P values (bottom) for support of compartmentalization for each region as determined in
the SM test. (B) KST* values (top) and corresponding P values (bottom) for support of compartmentalization between X4 and R5 variants for each
genome region as determined by the KST* test. Dashed line indicates a P value of 0.05.
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too small to be detected in our assay (62, 63), and monocytes
may not be productively infected and only produce virus upon
entry into tissue and differentiation (72, 84). Furthermore, the
decay characteristics of HIV-1 upon initiation of therapy that
includes an integrase inhibitor suggest that much of the second
phase of decay observed in conventional therapy represents
cells that are slowly undergoing integration and that the pro-
portion of productively infected, long-lived cells is smaller than
previously thought (53, 80). Another limitation of this study is
that it depends on the assumption that compartmentalized
subpopulations can be distinguished by their env genotypes
and, in particular, genotypes that can be resolved by HTA.
However, in addition to its function in determining host cell
tropism, the extreme genetic complexity of env within infected
individuals makes it a highly sensitive target for the detection
of coexisting viral subpopulations, and any other genomic re-
gion that may drive HIV-1 compartmentalization would likely
be linked to distinct env variants as a result of founder effects,
genetic isolation, or compartment-specific evolution. Further-
more, any compartmentalized variants would have likely di-
verged enough to be resolved by HTA analysis (30). Thus, we
can conservatively conclude that the lack of genetic compart-
mentalization and the differential decay rates observed in this
study apply to the bulk of the HIV-1 population in the periph-
eral blood that represents primarily the first phase of viral
RNA decay during HAART.
Another potential opportunity for cellular compartmental-
ization is between naïve and memory CD4 T cells. While
naïve and memory T cells express similar levels of CXCR4,
CCR5 is expressed only in memory cells (5, 46, 55). Previous
studies have found a wide range of preferential infection by,
and potential compartmentalization of, X4 and R5 variants in
these cell types in a manner consistent with their coreceptor
expression patterns (3, 57, 91). If X4 and R5 variants are
compartmentalized in these two cell types to a significant de-
gree, then similarity in decay rates would indicate that the life
spans of infected naïve and memory cells are similar when they
become activated and produce virus. It is thought that the bulk
of viral replication occurs in activated CD4 memory T cells
(34, 49, 62, 86, 88, 100), in which case any potential compart-
mentalization of R5 and X4 variants observed in resting mem-
ory and naïve cells may represent only a small fraction of the
total population. Also, activated and previously activated T
cells express both CCR5 and CXCR4 (5, 55, 58), providing a
potential source of mixing of R5 and X4 variants. There is
evidence to suggest that the pool of cells supporting the bulk of
virus replication is not homogeneous in its susceptibility to
infection by X4 and R5 variants (22) and that X4 and R5
variants may be differentially affected by antiretroviral therapy
(22, 66). However, we found no difference in the decay rates of
X4 and R5 variants upon initiation of therapy, and the decay
rates of these variants are within the range reported in other
studies for the first phase of decay, presumably reflecting the
life spans of the activated memory cells supporting 99% of
the virus population (34, 49, 62, 63, 96). This finding is consis-
tent with a model where virus is emerging from a homoge-
neous pool of cells that is sufficiently susceptible to infection by
both X4 and R5 variants to account for most of the production
of these variants found in the periphery. This is also further
supported by the finding of a lack of genetic compartmental-
ization between X4 and R5 populations in both subjects 101
and 109 for regions outside of env, indicating some overlap of
target cell types. However, the lack of data indicating differ-
ential decay rates of variants does not allow a definitive con-
clusion to be drawn regarding the half-lives of infected cells in
different cellular subsets until the degree of cellular compart-
mentalization of X4 and R5 variants can be more fully and
directly accounted for in studies of this type.
The divergent X4 and R5 lineages indicate some degree
of genetic compartmentalization between these variants.
This could be due to physical isolation in different cell types
or to genetic linkage selected across env for the ability to use
different coreceptors. However, we detected an overall lack
of compartmentalization and evidence of recombination be-
tween these populations in sequence regions increasingly
distal of 3 of V3, suggesting the potential for sequence
mixing between R5 and X4 variants in a coinfected cell (Fig.
6 and 7). This observation is consistent with previous reports
that have identified X4/R5 recombinants both within env
and between env and other regions of the genome (51, 77,
92). However, our use of the single genome amplification
approach avoided the possibility of recombination during
PCR, which may have created artificial recombinants in
some previous studies. These data support the conclusion
that while X4 and R5 variants may preferentially replicate in
distinct cellular compartments, they are not genetically iso-
lated and must with some frequency infect the same cell
types. Still, the deep branch points in the phylogenetic trees
suggest that the initial outgrowth of X4 variants is from a
monoclonal genotype.
This study found little evidence for differential decay and
compartmentalization of env variants comprising the bulk of
the virus in the peripheral blood, even in the case of divergent
coreceptor phenotypes, indicating that HAART is equally ef-
fective on all the detectible variants making up the bulk virus
in the peripheral blood. However, new technologies are be-
coming available that will allow sampling to below 1% (52),
and the application of these technologies may yet reveal minor
populations that exhibit differential rates of decay upon initi-
ation of therapy.
FIG. 7. Representative examples of recombination between X4 and R5 variants in subjects 1551 (A) and 411 (B) Top panels show bootscanning
plots identifying recombination breakpoints. The horizontal axis indicates the nucleotide position in the putative recombinant (query sequence)
and in the genomic regions mapped within the plot. The vertical axis is the percent bootstrap support (1,000 replicates) for clustering of the query
sequence with either the R5 (gray) or X4 (black) putative parental sequences. Bottom panels show maximum-likelihood trees of V3 (left) and U3
(right) regions indicated in the bootscan plots. X4 variants are italicized and bolded. Recombinants are boxed and putative parents are circled.
LTR, long terminal repeat.
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